Tepotinib is an orally bioavailable quinoline-based, reversible ATP-competitive inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase, delivering low-nanomolar selectivity, blocking MET phosphorylation, inducing autophagy, and suppressing non-small-cell lung cancer.
Usually ships within 24 hours.